Researchers Isolate Protein Domain Linked to Tumor Progression
Tuesday, February 17, 2009 - 18:56
in Health & Medicine
(PhysOrg.com) -- When a promising cancer drug reached clinical trials in the 1990s, researchers were disappointed by the debilitating side effects that limited the trials. The drug inhibited a family of enzymes known as matrix metalloproteinases (MMPs). Now, researchers at Rensselaer Polytechnic Institute have shown that creating drugs that inactivate a different part of the MMP enzyme could have the capacity to target the tumor without the damaging side effects. Their findings, which hold promise for improved cancer therapies, were published Feb. 5 in the online Early Edition of the Proceedings of the National Academy of Sciences (PNAS).
Read the whole article on Physorg
More from Physorg
Related
- Researchers isolate protein domain linked to tumor progressionTue, 17 Feb 2009, 18:57:15 EST
- Revolutionary drug could be new hope for adrenal cancer patientsTue, 22 Sep 2009, 12:50:19 EDT
- Enzyme may hold key to improved targeting of cancer-fighting drugsThu, 29 May 2008, 17:07:50 EDT
- Twin nanoparticle shown effective at targeting, killing breast cancer cellsTue, 10 Mar 2009, 11:17:25 EDT
- New drug shows promise in treating drug-resistant prostate cancerFri, 10 Apr 2009, 10:24:39 EDT